

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



Boa3

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/17 // (A61K 38/17, 31:565)</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/03686</b> <b>(43) International Publication Date:</b> 6 February 1997 (06.02.97)
<b>(21) International Application Number:</b> PCT/EP95/02767 <b>(22) International Filing Date:</b> 14 July 1995 (14.07.95) <b>(71) Applicant (for all designated States except US):</b> APPLIED RESEARCH SYSTEMS [NL/NL]; ARS Holding N.V., 14 John B. Gorsiraweg, Curacao (AN). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BOE, Alessandra [IT/IT]; Via F. Mauriac, 22, I-00143 Rome (IT). BORRELLI, Francesco [IT/IT]; Via R. De Cesari, 119, I-00119 Rome (IT). <b>(74) Agent:</b> VANNINI, Mario; Istituto Farmacologico Sersono S.p.A., Via Casilina, 125, I-00176 Rome (IT).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TNF RECEPTOR AND STEROID HORMONE IN A COMBINED THERAPY  <b>(57) Abstract</b>  The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified treatment. In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## TNF RECEPTOR AND STEROID HORMONE IN A COMBINED THERAPY

### FIELD OF THE INVENTION

5       The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified  
10 treatment.

      In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.

### 15   BACKGROUND OF THE INVENTION

      Septic shock as a consequence of Gram-negative bacteremia or endotoxemia remains a critical clinical condition in spite of adequate antibiotic therapy.

      It is now known that the lethal consequences of septic shock results from  
20 an exaggerated host response, mediated by protein factors such as TNF and interleukin 1 (IL-1), rather than from the pathogen directly.

      Tumour necrosis factor (TNF) is a cytokine produced mainly by activated macrophages, which elicits a wide range of biological effects. These include an important role in endotoxic shock and in inflammatory, immunoregulatory,  
25 proliferative, cytotoxic and anti-viral activities.

      The induction of the various cellular responses mediated by TNF is initiated by its interaction with two distinct cell surface receptors of approximately 55 kDa (also called TNF-R1) and 75 kDa (also called TNF-R2). The extracellular soluble portions of these receptors, called respectively TBP-1  
30 (TNF Binding Protein-1) and TBP-2 (TNF Binding Protein-2), have been isolated and cloned (see EP Patents 308 378, 398 327 and EP patent Application 433 900).

      Several studies in animal models of TNF-mediated endotoxic shock indicated that both anti-TNF antibodies and soluble TNF-receptor are able to  
35 counteract the lethal effects induced (see for example: Bentler, B et al., Science,

229:869 (1985), Lesslauer, W. et al., Eur. J. Immunol., 21:2883 (1991), Evans, T.J. et al, J. Exp. Med., 180:2173 (1994) and Mohler K.M. et al., J. Immunol. 151:1548 (1993)).

5 The *in vivo* protective effects of urinary as well as recombinant TBP-1 (derived from both CHO and *E. Coli* cells) in experimental models of septic shock have already been demonstrated (see Bertini, R. et al., Eur. Cytokine Netw. 4(1):39 (1993) and Ythier A., et al., Cytokines, 5:459 (1993)).

10 DHEA (INN: Prasterone) is an adrenocortical steroid hormone which is an intermediate in the biosynthesis of other hormones including testosterone and estradiol-17 $\beta$ .

The precise biological functions of DHEA are still unclear. Experimental and epidemiological data suggest an inverse relationship between low levels of DHEA in serum and morbidity from atherosclerotic cardiovascular disease (see Barret-Connor, D. et al., N. Engl. J. Med. 315:1519 (1986)), cancer (see Gordon, 15 G.B., et al., Cancer Res. 51:1366 (1991)) and immunodeficiency virus (HIV) infection (Villette, J.M. et al. J. Clin. Endocrinol. Metab. 70:572 (1990)).

An immunomodulating activity of this drug has also been reported; in particular, DHEA has been shown to prevent the development of systemic lupus erythematosus in a mouse model (Lucas, J. et al. J. Clin. Invest. 75:2091 (1985)).

20 It has been demonstrated that DHEA regulates the systemic resistance against lethal viral infections induced by different viruses: coxsackievirus B4 (as reported in Loria, R.M. et al., Ann. N.Y. Acad. Sci, 293), herpes virus type 2 (see Loria, R.M. et al., J.Med. Virol., 26:301 (1988)), West Nile virus (a neurovirulent Sindbis virus) and Semliki Forest virus (as reported in Ben-Nathan, 25 D. et al. Arch. Virol. 20:263 (1989)).

It has also been reported that DHEA has similar protective effects against a lethal bacterial infection induced by *Enterococcus faecalis* (see Loria, R.M. et al. in Symposium Pharmaco-Clinique, Roussel-Uclaf 9:24 (1989)).

30 Danenberg, H.D. et al. (Antimicrob. Agents Chemother.36:2275 (1992)) reported that DHEA has the capability of protecting mice from septic shock induced by lipopolysaccharides (LPS) alone or by Tumor Necrosis Factor alpha (TNF- $\alpha$ ) in combination with D-Galactosamine. LPS administration resulted in high levels of TNF- $\alpha$ , a response that was significantly blocked by DHEA, both *in vivo* and *in vitro*.

### DISCLOSURE OF THE INVENTION

The main object of the present invention is the use of a TNF Receptor in combination with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. The TNF Receptor and the steroid hormone can be administered simultaneously, separately or sequentially.

The Applicant has, in fact, found that in such treatment there is a synergic effect between the two active ingredients.

Another object of the present invention is, therefore, the method for treating lethal bacterial and viral infections as well as autoimmune and inflammatory diseases by administering simultaneously, separately or sequentially an effective amount of TNF Receptor and an effective amount of a steroid hormone, together with a pharmaceutically acceptable excipient.

A further object of the present invention are the pharmaceutical compositions containing a TNF Receptor and a steroid hormone, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential administration of its active ingredients in the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases.

In case of separate or sequential use of the two active ingredients, the pharmaceutical compositions of the invention will consist of two different formulations, each comprising one of the two active ingredients together with one or more pharmaceutically acceptable excipients.

The administration of such active ingredients may be by intravenous, intramuscular or subcutaneous route. Other routes of administration, which may establish the desired blood levels of the respective ingredients, are comprised by the present invention.

Non-limitative examples of pathologies, in which the above active ingredients are indicated, are the following: septic shock, AIDS, rheumatoid arthritis, lupus erythematosus and multiple sclerosis. Particularly preferred is the treatment of septic shock.

The TNF Receptor is preferably selected between the extracellular soluble domain of TNF-R1, i.e. TBP-1, and the extracellular soluble domain of TNF-R2, i.e. TBP-2. TBP-1 is particularly preferred. Recombinant human TBP-1 (r-hTBP-1) is advantageously used according to the invention.

The steroid hormone can be both a corticosteroid or an androgen. Preferably, it is an androgen. More preferably, it is DHEA or one of its metabolites, dispersed in a suitable medium; for example a phospholipid emulsion or carboxymethyl cellulose or polyvinylpyrrolidone.

5 Therefore, a preferred embodiment of the invention consists in the combined use of r-hTBP-1 and DHEA in the treatment of septic shock. In this case, the Applicant has found that it is possible to reduce at least four times the effective dose of r-hTBP-1.

The above effect has been showed with *in vivo* experiments in mice.

10 In particular, a murine model has been used in the present invention, according to which septic shock is induced by administering lipopolysaccharides (LPS) in combination with D-Galactosamine.

For the human therapy the preferred doses of the active ingredient are 20 mg of r-hTBP-1 and 80 mg of DHEA, preferably divided into four  
15 administrations in a 24-hours period.

The invention will now be described by means of the following Examples, which should not be construed as in any way limiting the present invention. The Examples will refer to the Figures specified here below.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Protective effects of CHO r-hTBP-1 (62.5 µg/mouse) in combination with single (250 µg/mouse) or repeated injections (4 x 62.5 µg/mouse) of DHEA in the experimental murine septic shock are shown.

25 Figure 2: Protective effects of different doses of CHO r-hTBP-1 in the experimental murine septic shock induced by LPS + D-Galactosamine are shown for comparative purposes. The number of mice in the r-hTBP-1 groups is the same as that reported for the corresponding control groups. In Figure 2a and 2b are shown the results observed after 24 and 48 hours (respectively) after the inoculum of LPS + D-Galactosamine.

30

## EXAMPLE 1

### **LPS + D-Galactosamine-induced septic shock model**

The experiments were carried out *in vivo* on mice. The septic shock was induced by an i.p. administration of a mixture of LPS (0.1 µg/mouse) and  
35 D-Galactosamine (18 mg/mouse).

The treatment schedule for r-hTBP-1 based on repeated administrations (the total dose was divided into 4 administrations given at time 0 and 3, 6 and 24 hours after), was adopted. CHO r-hTBP-1 was tested, alone or in combination with DHEA, at dose levels of 62.5 and 125 µg/mouse (total dose).

5 **Assessment of the effects of DHEA in the LPS + D-Galactosamine model**

DHEA was tested both in a single administration injected i.p. one hour before and contemporaneously to the septic shock-inducing agent at doses encompassed between 100 and 2,000 µg/mouse and in repeated treatment with the total dose (250 µg/mouse) divided into 4 injections given within 24 hours.

10 **Assessment of the effects of DHEA in combination with r-hTBP-1**

The above treatment schedules of DHEA (doses from 250 to 1,500 µg/mouse) were followed also in combination with r-hTBP-1 which was tested at the total dose varying from 62.5 to 125 µg/mouse (divided into 4 administrations).

15 **Materials**

Animals

SPF female BALB/c inbred mice, 6-8 weeks (about 18-20 g b.w.), from Charles River were used throughout the whole study after an acclimatisation period of at least 7 days.

20 Unless otherwise specified in all the experiments the mice were randomly divided into groups of 10 animals each.

Test drugs

CHO recombinant human TBP-1 produced according to the known methods in the field of biotechnology.

25 The protein mass of the r-hTBP-1 bulk was determined by the Lowry method before starting the experiments.

*E. Coli* lipopolysaccharides 055:B5 supplied by Sigma.

D-(+)-Galactosamine hydrochloride, 99% supplied by Janssen.

Dehydroepiandrosterone supplied by Sigma.

30 Reagents

Sodium chloride 0.9% (Saline), manufactured by Baxter.

Phospholipid emulsion (PLE) composed of phosphatidyl choline (71%), phosphatidyl ethanolamine (16%), lysophosphatidyl choline (7.5%), sphingomyelin (5%) and phosphatidic acid (0.3%).

## Methods

### Septic shock model (LPS + D-Galactosamine model)

Both substances were dissolved in saline. The mixture of LPS (0.1  $\mu$ g/mouse) and D-Galactosamine (18 mg/mouse) was prepared by mixing equal volumes of these substances. The mixture was subsequently injected to animals by i.p. route. This dose was selected under previous experiments as that inducing around 80% mortality calculated as the number of dead vs. total number of mice for each group. The lethality was monitored after 24, 48, 72 and 96 hours and at day 7 post-treatment.

### Treatment schedule for r-hTBP-1

The drug was diluted in saline and injected by repeated administrations, i.e. i.v. immediately before the inoculum of LPS plus D-Galactosamine and s.c. 3, 6 and 24 hours later.

### Treatment schedules for DHEA

The effects of DHEA, alone or in combination with r-hTBP-1, were assayed after single i.p. administrations at different times in respect to LPS + D-Galactosamine injection; in particular, it was administered 1 hour before and contemporaneously to the septic shock-inducing agent.

A repeated treatment schedule was also investigated in which DHEA was administered at time 0 (septic shock induction) and 3, 6 and 24 hours later. DHEA was initially vehicled in a mixture of 2.5% alcohol and 10% rabbit serum in saline. To improve the solubility and standardise the preparation, the steroid was successively dispersed in a mixture of 2.5% alcohol and 10% phospholipid emulsion in saline.

### Data evaluation

The primary end point was the survival rate at 48 hours after induction of septic shock. The comparison of the effects of each treatment group vs. controls and among treatment groups was effected by Fisher's exact test, one-tailed. The same comparison was also performed at the other time points. The results in each treatment group were expressed as percent survival.

## Results

### DHEA administered 1 hour before LPS + D-Galactosamine

The results of the DHEA dose-range finding experiments are reported in Table 1. No protective effects were exerted by this substance up to 1,000  $\mu$ g/mouse; by contrast, statistically significant protective effects were obtained at



higher doses with a complete protection at 2,000 µg/mouse at all time points considered.

When a suboptimal dose of CHO r-hTBP-1 (125 µg/mouse), inducing about 50% survival, was administered in combination with two suboptimal doses of DHEA (1,000 and 1,500 µg/mouse) an additive effect between the two substances was observed (Table 2). The result of the combination with the highest DHEA dose, where a 100% survival rate was obtained, is significantly different from that of the r-hTBP-1 group (50%) and DHEA group (40%).

DHEA administered contemporaneously with LPS + D-Galactosamine

The results obtained in the DHEA dose-range finding test, where the substance, diluted in saline 10% rabbit serum, was administered contemporaneously to septic shock induction are reported in Table 3.

Although a clear dose-effect relationship has not been found, a higher protection was produced by 1,000 µg DHEA in comparison to what observed with the same dose by the previous treatment schedule (DHEA administered 1 hour before).

The combination of 62.5 µg/mouse of r-hTBP-1 with 250 µg/mouse of DHEA induced a slightly higher protection (60%) in respect to the single treatments (20% and 30% for r-hTBP-1 and DHEA, respectively, see Table 4). When the same combination was vehicled in a 10% phospholipid emulsion, to improve the solubility of DHEA, a significantly higher survival was obtained compared to DHEA and r-hTBP-1 alone (Table 4) at 24 hours which, however, successively decreased.

Repeated administrations of DHEA after LPS + D-Galactosamine

Comparable results (30 and 40% survival rate at 48 hours) were obtained when a dose of 250 µg/mouse of DHEA was administered as a single injection (Table 5, group D) or divided into 4 inocula (given at 0, 3, 6 and 24 hours from septic shock induction, group E), respectively. Similarly, no statistically significant differences were found when the animals were injected the combination of r-hTBP-1 and DHEA with the latter administered either as a single inoculum (Table 5, group F) or divided into 4 injections (Group G).

Due to the high survival rate obtained in the r-hTBP-1 group an additive effect is not evident in these tests after 24 and 48 hours where the combination-treated groups were significantly different only from control and DHEA groups.

However, it has to be stressed that the combined therapy induced a more

prolonged survival in respect to the r-hTBP-1 group alone since a statistically significant difference was found after 72 and 96 hours.

Figure 1 reports the data obtained combining the results of the three experiments reported in Tables 4 and 5 in which the dose of 250 µg/mouse of DHEA was injected as a single inoculum or divided into 4 inocula (62.5 µg each).

Figure 2 reports, for comparative purposes, the effects of different doses of CHO r-hTBP-1 alone in the experimental murine septic shock induced by LPS + D-Galactosamine. The number of mice in the r-hTBP-1 groups is the same as that reported for the corresponding control groups. In Figure 2a and 2b are shown the results observed after 24 and 48 hours (respectively) after the inoculum of LPS + D-Galactosamine.

In all the experiments percent survival values were calculated using the survival Tables for the *follow up* studies (Armitage P., Cap. XIV, Tavole di sopravvivenza in Statistica Medica, Feltrinelli, Milano). The  $\chi^2$ -test was applied to each observation time by comparing the DHEA + r-hTBP-1 groups to the other groups.

In addition to showing that at all time points the combined therapy is significantly different from control and DHEA groups, this analysis confirmed that more prolonged survival times were obtained with the combined treatment in respect to r-hTBP-1 alone. Although no statistical difference between the two treatment combinations has been found, a trend to a more sustained protection can be observed when both drugs were divided into four injections, which is reflected by the different levels of significance at different time-points (Table 6).

## 25 Conclusions

A significant protection from death (70% survival) was found with at least 1,500 µg/mouse of DHEA, injected 1 hour before LPS + D-Galactosamine, which confirm literature data.

When suboptimal doses of DHEA (1,000 and 1,500 µg/mouse) and of r-hTBP-1 (125 µg/mouse, total dose) were combined, additive effects (90-100% survival) were produced, compared to 0-40% and 50% with the two doses of DHEA and of r-hTBP-1, respectively.

Similar results were obtained even with lower doses of DHEA (250 µg/mouse) in combination with r-hTBP-1 (62.5 µg/mouse) (90-100% survival), which also provided a more prolonged protection (up to 96 hours) in respect to r-

hTBP-1 alone, both when DHEA was injected contemporaneously to LPS + D-Galactosamine in a single inoculum (250 µg/mouse) or when the same dose was divided into 4 inocula (62.5 µg/each) injected at times 0, 3, 6 and 24 hours after septic shock induction.

- 5        The present findings are of particular relevance in showing that a combined treatment of r-hTBP-1 with DHEA allows to reduce the dose of r-hTBP-1 by at least four times.

## EXAMPLE 2

10

### **Example of pharmaceutical manufacturing**

#### **A) r-h-TBP-1**

#### 15    Materials

Pure saccharose Ph EurBP, Ph Nord, NF, (Merck); H<sub>3</sub>PO<sub>4</sub> Suprapur (Merck); NaOH for analysis (Merck); water for injectable.

- 20        Vials DIN 2R (borosilicate glass type I), rubber closures (Pharmagummi W1816 V50) and Aluminium rings and Flip-off caps (Pharma-Metal GmbH) are used as containers.

#### Preparation of r-hTBP-1 solution containing saccharose (for 1,000 vials each containing 5 mg of r-hTBP-1)

- 25        Saccharose (30.0 g) and H<sub>3</sub>PO<sub>4</sub> (1.96 g) are dissolved into water for injectables (800 ml) in order to obtain the starting saccharose solution.

- 30        The bulk of r-hTBP-1 (5 g) is added to the saccharose solution that, after the pH has been adjusted at 7.0 by means of 2.5 M NaOH, is brought to the final volume of 1,000 ml. The solution is filtered through a 0.22 µm Duarapore sterile filter (Millipore). During the process, the solution temperature is kept between 4° and 8°C.

#### Filling up and lyophilisation

- 35        The vials are filled up with 1 ml of r-hTBP-1 sterile solution, transferred to the freeze dryer and cooled at -45°C for 6 hours. The lyophilisation is started at the temperature of -45°C with a vacuum of 0.07 mBar. The heating is performed

according to the following scheme: 10°C for 12 hours; then +35°C until the end of the cycle.

## B) DHEA

5

### Materials

Pure Mannitol Ph Eur, BP, FU, USP, FCC, E241 (Merck);  $H_3PO_4$  Suprapur (Merck); NaOH for analysis (Merck); water for injectable.

10 Vials DIN 2R (borosilicate glass type I), rubber closures (Pharmagummi W1816 V50) and Aluminium rings and Flip-off caps (Pharma-Metal GmbH) are used as containers.

### Preparation of DHEA solution containing mannitol (for 1,000 vials containing 10 mg of DHEA)

15 Mannitol (45.0 g) and  $H_3PO_4$  (1.96 g) are dissolved into water for injectables (800 ml) in order to obtain the starting saccharose solution.

The bulk of DHEA (20 g) is added to the saccharose solution that, after the pH has been adjusted at 7.0 by means of 2.5 M NaOH, is brought to the final volume of 1,000 ml. The solution is filtered through a 0.22  $\mu m$  Durapore sterile filter (Millipore). During the process, the solution temperature is kept between 20 4° and 8°C.

### Filling up and lyophilisation

The vials are filled up with 1 ml of DHEA sterile solution, transferred to 25 the freeze dryer and cooled at -45°C for 6 hours. The lyophilisation is started at the temperature of -45°C with a vacuum of 0.07 mBar. The heating is performed according to the following scheme: +20°C for 12 hours; then +35°C until the end of the cycle.

30

Table 1 - Effects of DHEA in the septic shock induced by LPS + D-Galactosamine, in mice

Treatment, dose / mouse and route	No. of mice	% cumulative survival							
		24 hrs		48 hrs		72 hrs		96 hrs	
		1st exp	2nd exp	1st exp	2nd exp	1st exp	2nd exp	1st exp	2nd exp
LPS 0.1 µg, i.p. (1) + D-Gal. 18 mg, i.p. (1)	None	20	20	20	10	20	10	20	10
	DHEA, i.p. 100 µg (2)	20	-	20	-	20	-	20	-
	DHEA, i.p. 500 µg (2)	10	-	10	-	10	-	10	-
	DHEA, i.p. 1 000 µg. (2)	-	20	-	20	-	10	-	0
	DHEA, i.p. 1 500 µg. (2)	-	70 a	-	70 a	-	50	-	50
DHEA, i.p. 2 000 µg. (2)	10	100 a	100 a	100 a	100 a	100 a	100 a	100 a	100 a

(1) Administered as a mixture at time 0;

(2) Administered 1 hour before LPS + D-Gal administration  
(a) Significantly different from LPS + D-Gal controls (Fisher's exact test, one-tailed)

N.B. DHEA was vehicled in saline 10% rabbit serum

- 12 -

Table 2 - Effects of CHO r-hTBP-1 and DHEA in septic shock induced by LPS + D-Galactosamine, in mice

Treatment, dose/mouse and route		No. of Mice	% cumulative survival			
			24 hrs	48 hrs	72 hrs	96 hrs
LPS, i.p. 0.1 µg, (1)	None	10	10	10	10	10
	r-hTBP-1 125 µg (2)	10	50	50	50	50
	DHEA 1 000 µg, i.p. (3)	10	0	0	0	0
	DHEA 1 500 µg, i.p. (3)	10	40	40	20	20
+ D-Gal, i.p. 18 mg, (1)	DHEA 1 000 µg, i.p. (3)	10	90 a, b	90 a, b	90 a, b	90 a, b
	r-hTBP-1 125 µg (2)	10	90 a, b	90 a, b	90 a, b	90 a, b
	DHEA 1 500 µg, i.p. (3)	10	100 a, b, c	100 a, b, c	100 a, b, c	100 a, b, c
	r-hTBP-1 125 µg (2)	10	100 a, b, c	100 a, b, c	100 a, b, c	100 a, b, c

(1) Administered as a mixture at time 0; (2) Administered at time 0 (i.v.), and at 3, 6 and 24 hours (s.c.) after LPS + D-Gal injection.  
 (3) Administered 1 hour before LPS + D-Gal administration;  
 (a) Significantly different from LPS + D-Gal. controls; (b) Significantly different from DHEA alone; (c) Significantly different from r-hTBP-1 alone (Fisher's exact test, one-tailed) N.B. - DHEA was vehicled in saline 10% rabbit serum.

Table 3 - Effects of DHEA in the septic shock induced by LPS and D-Galactosamine, in mice

Treatment, dose/mouse and route	No of mice	% cumulative survival					
		24 hrs		48 hrs		72 hrs	
		1st exp.	2nd exp.	1st exp.	2nd exp.	1st exp.	2nd exp.
LPS 0.1 µg, i.p. (1)  + D-Gal. 18 mg, i.p. (1)	None	10	40	10	40	10	40
	DHEA, i.p. 250 µg (2)	-	20	-	20	-	20
	DHEA, i.p. 500 µg. (2)	50	30	40	30	30	30
	DHEA, i.p. 750 µg (2)	40	50	40	50	40	50
	DHEA, i.p. 1 000 µg. (2)	80 <sup>a</sup>	-	60	-	60	-

(1) Administered as a mixture at time 0

(2) Administered at time 0

<sup>a</sup> Significantly different from LPS + D-Gal controls (Fisher's exact test, one-tailed)

N.B.: DHEA was vehicled in saline 10% rabbit serum

**Table 4 - Effects of CHO r-hTBP-1 and DHEA in the septic shock induced by LPS and D-Galactosamine, in mice**

<i>Treatment, dose / mouse and route</i>		<i>No. of mice</i>	<i>% cumulative survival</i>			
			<i>24 hr</i>	<i>48 hr</i>	<i>72 hr</i>	<i>96 hr</i>
LPS 0.1µg i.p. (1)  + D-Gal 18mg i.p. (1)	none	20	25	25	25	25
	r-hTBP-1, 62.5 µg (2)	10	20	10	0	0
	DHEA 250 µg (3) (NaCl 10%RS)	10	30	30	30	30
	DHEA 250 µg (3) (NaCl 10%RS) + r-hTBP-1 62.5 µg (2)	10	60	50	50	50
	DHEA 250 µg (3) (NaCl 10% PLE)	10	40	30	30	30
	DHEA 250 µg (3) (NaCl 10% PLE) + r-hTBP-1 62.5 µg (2)	10	90 a,b,c	60 c	40 c	40 c

(1) Administered as a mixture at time 0

(2) Administered at time 0 (i.v.) and at 3, 6 and 24 hours (s.c.) after LPS + D-Gal. injection.

(3) Administered as a single injection at time 0 i.p.

(a) Significantly different from LPS + D-Gal. controls (Fisher's exact test, one-tailed).

(b) Significantly different from DHEA alone (Fisher's exact test, one-tailed).

(c) Significantly different from r-hTBP-1 alone (Fisher's exact test, one-tailed).

N.B. DHEA was vehicled in saline 10% rabbit serum (NaCl 10% RS) or in saline 10% phospholipid emulsion (NaCl 10% PLE).



Table 5 - Effects of CHO r-hTBP-1 and DHEA in the septic shock induced by LPS + Galactosamine, in mice

Treatment dose/mouse and route		No. of mice	% cumulative survival									
			24 hrs		48 hrs		72 hrs		96 hrs			
			1st exp.	2nd exp.	1st exp.	2nd exp.	1st exp.	2nd exp.	1st exp.	2nd exp.		
LPS	A	None	10	10	10	10	10	10	10	10		
	B	NaCl 10% PLE	-	11 (n=9)	-	11 (n=9)	-	11 (n=9)	-	11 (n=9)		
0.1 µg, i.p. (1) + D-Gal. 18 mg, i.p. (1)	C	r-hTBP-1 62.5 µg (2)	90a	70a	80a	40	70a	30	70a	30		
	D	DHEA 250 µg (3)	40	-	30	-	30	-	30	-		
	E	DHEA 62.5µg x4 (4)	40	40	40	40	40	40	40	40		
	F	DHEA 250 µg (3) + r-hTBP-1 62.5 µg (2)	100a,b	-	100a,b	-	100a,b	-	100a,b	-		
G		DHEA 62.5µg x4 (4)	100a,b	90a,b	100a,b	90a,b	100a,b	80a,c	100a,b	80a,c		
		r-hTBP-1 62.5 µg (2)	10									

The notes to the table are reported in the next page

## Notes to Table 5

- (1) Administered as a mixture at time 0  
 (2) Administered at time 0 i.v., and at time 3, 6 and 24 hours (s.c.)  
 (3) Administered as a single injection at time 0 i.p.  
 (4) Administered at time 0, 3, 6 and 24 hours i.p.  
 (a) Significantly different from LPS + D-Gal. controls (Fisher's exact test, one-tailed).  
 (b) Significantly different from DHEA alone (Fisher's exact test, one-tailed).  
 (c) Significantly different from r-hTBP-1 alone (Fisher's exact test, one-tailed).  
 N.B. DHEA was vehicled in 10% phospholipid emulsion (NaCl 10% PLE)

**Table 6 - Statistical significance of r-hTBP-1 group vs. r-hTBP-1 + DHEA groups ( $\chi^2$ -test)**

<b>Observation times (hours post LPS + D-Gal injection)</b>	<b><i>p level</i></b>	
	<b><i>r-hTBP-1 vs. r-hTBP-1 62.5 + DHEA 250 (1)</i></b>	<b><i>r-hTBP-1 vs. r-hTBP-1 62.5 + DHEA 4x62.5 (1)</i></b>
24	0.015	0.015
48	0.022	0.0006
72	0.024	0.0002
96	0.024	0.0002

(1) Doses are expressed as  $\mu\text{g}/\text{mouse}$ .

- 17 -


CLAIMS

1. Use of a TNF Receptor in combination with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections.
2. Use of a TNF Receptor in combination with a steroid hormone to produce a pharmaceutical composition for the treatment of autoimmune and inflammatory diseases.
3. The use according to Claim 1 or 2, wherein the TNF Receptor and the steroid hormone are used simultaneously, separately or sequentially.
4. The use according to any preceding claim, wherein the TNF Receptor is selected between the extracellular soluble domain of TNF-R1, TBP-1 and the extracellular soluble domain of TNF-R2, TBP-2.
5. The use according to any preceding claim, wherein the TNF Receptor is the extracellular soluble domain of TNF-R1, TBP-1.
6. The use according to any preceding claim, wherein the steroid hormone is selected between a corticosteroid and an androgen.
7. The use according to claim 6, wherein the steroid hormone is an androgen.
8. The use according to claims 6 or 7, wherein the androgen is DHEA.
9. The use according to claim 1, wherein the lethal bacterial infection is septic shock.
10. Pharmaceutical composition containing a TNF receptor and a steroid hormone, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in the treatment of lethal bacterial and viral infections.
11. Pharmaceutical composition containing a TNF receptor and a steroid hormone, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in the treatment of autoimmune and inflammatory diseases.
12. The pharmaceutical composition according to claim 10 or 11, wherein the TNF Receptor is selected between the extracellular soluble domain of TNF-R1, TBP-1 and the extracellular soluble domain of TNF-R2, TBP-2.
13. The pharmaceutical composition according to claims 10 or 12, wherein the TNF Receptor is the extracellular soluble domain of TNF-R1, TBP-1.

- 18 -

14. The pharmaceutical composition according to any of claims 10 to 13, wherein the steroid hormone is selected between a corticosteroid and an androgen.
15. The pharmaceutical composition according to any of claims 10 to 14, wherein the steroid hormone is an androgen.
16. The pharmaceutical composition according to any of claims 10 to 15, wherein the androgen is DHEA.
17. The pharmaceutical composition according to claim 10, wherein the lethal bacterial infection is septic shock.


Figure 1



a = significantly different from r-hTBP-1 group ( $\chi^2$ -test)

b = significantly different from control group ( $\chi^2$ -test)


Figure 2 a



**b** = significantly different from control group ( $\chi^2$ -test)

Figure 2 b

48 hours post LPS + D-Gal injection



b = significantly different from control group ( $\chi^2$ -test)

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02767

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K38/17 //(A61K38/17,31:565)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,92 13095 (SYNERGEN INC) 6 August 1992 see the whole document ---	1-17
Y	SCHWEIZ. MED. WSCHR., vol. 123, no. 11, 1993, pages 480-491, XP002021545 E. GIRARDIN ET AL.: "Cytokines et antagonistes dans le choc septique" see the whole document ---	1-17
Y	EP,A,0 512 528 (YEDA RES & DEV) 11 November 1992 see the whole document ---	2-8, 11-16
Y	WO,A,94 06476 (IMMUNEX CORP) 31 March 1994 see the whole document ---	2-8, 11-16
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 December 1996

Date of mailing of the international search report

10.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stierman, B



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02767

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,95 03827 (KENNEDY INST OF RHEUMATOLOGY ;TURK JOHN LESLIE (GB); BAKER DAVID () 9 February 1995 see the whole document see claims 13,21,22 ---	2-8, 11-16
Y	PROGRAM AND ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 33, no. 0, 1993, page 378 XP002021546 S.M. OPAL ET AL.: "Tumor Necrosis Factor Receptor-Fc Fusion Protein (sTNFR:Fc) in the treatment of experimental Pseudomonas sepsis" see abstract ---	1,3-10, 12-17
Y	BIOMED PHARMACOTHER, vol. 48, no. 10, 1994, pages 417-424, XP002021547 E. TARTOUR ET AL.: "Anti-cytokines: promising tools for diagnosis and immunotherapy" see the whole document ---	1-17
Y	LYMPHOKINE AND CYTOKINE RESEARCH, vol. 12, no. 5, 1993, page 377 XP002021548 D. RUSSELL ET AL.: "Synergistic protection against lethal endotoxemia by treatment with Interleukin-1 receptor antagonist and tumor necrosis factor binding protein" see abstract ---	1,3-10, 12-17
Y	ANTIMICROB AGENTS CHEMOTHER, vol. 36, no. 10, 1992, pages 2275-2279, XP002021549 H.D. DANENBERG ET AL.: "Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production" cited in the application see the whole document ---	1-17
Y	ARTHRITIS & RHEUMATISM, vol. 37, no. 9 suppl., 1994, page s407 XP002021550 R.F. VAN Vollenhoven ET AL.: "In patients with Systemic Lupus Erythematosus, treatment with oral dehydroepiandrosterone restores abnormally low in vitro production of IL-2,IL-6 and TNF-alpha" see abstract --- -/--	2-8, 11-16

# INTERNATIONAL SEARCH REPORT

Inter mal Application No  
PCT/EP 95/02767

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AIDS RES HUM RETROVIRUSES, vol. 9, no. 8, 1993, pages 747-754, XP002021551 J.Y. YANG ET AL.: "Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA" see the whole document ---	1,3-10, 12-16
Y,0	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, BASIS FOR CANCER MANAGEMENT. CONFERENCE ON PROPEDEUTICS TO CANCER MANAGEMENT, ERICE, ITALY, APRIL 1-6,1995, vol. 784, 1996, pages 237-251, XP002021552 M. CUTOLO ET AL.: "Immunomodulatory mechanisms mediated by sex hormones in rheumatoid arthritis" see the whole document ---	2-8, 11-16
Y	BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, no. 1, 1988, pages 402-409, XP002021553 F.C. KULL: "Reduction in tumor necrosis factor receptor affinity and cytotoxicity by glucocorticoids" see the whole document ---	1-6, 9-14,17
Y	DATABASE MEDLINE Abstr. No. 95151042, XP002021554 see abstract & ARTHRITIS RHEUM, vol. 38, no. 2, February 1995, pages 151-160, W.P. AREND ET AL.: "Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis" -----	1-17

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/02767

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-17  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
Expressions like "a TNF receptor", "a steroid hormone", "a corticosteroid" or "an androgen" do not make sufficiently clear, which specific compounds are meant. The search has been restricted to the compounds explicitly mentioned in the claims and to the general inventive concept.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/02767

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO-A-9213095	06-08-92	AU-A-	1235692	27-08-92
		AU-A-	4228896	18-04-96
		CA-A-	2100329	19-07-92
		EP-A-	0567566	03-11-93
		JP-T-	6506446	21-07-94
-----				
EP-A-0512528	11-11-92	AU-A-	1609492	12-11-92
		CA-A-	2068027	08-11-92
		JP-A-	5170661	09-07-93
		US-A-	5512544	30-04-96
-----				
WO-A-9406476	31-03-94	AU-B-	670125	04-07-96
		AU-A-	4920993	12-04-94
		CA-A-	2123593	31-03-94
		EP-A-	0620739	26-10-94
		JP-T-	7504203	11-05-95
		NO-A-	941780	15-07-94
-----				
WO-A-9503827	09-02-95	AU-A-	4719093	28-02-95
		EP-A-	0710121	08-05-96
-----				